What changed
The bigger item is the Amended and Restated Coty Inc. Equity and Long-Term Incentive Plan, which adds 50 million shares of Class A Common Stock to its available share reserve. The board had approved that increase before the meeting, pending a stockholder vote. A second plan, the Amended and Restated Coty Inc. Stock Plan for Directors, adds 2 million shares to its reserve on the same terms.
For the ELTIP, the count was 642,428,535 for, 66,772,884 against, 3,185,019 abstaining and 35,399,214 broker non-votes. That is a clear majority, but the against column is about one share in ten of the votes cast. The director plan passed with 709,753,217 for and 2,543,721 against.
The meeting had a quorum of 82.67 percent of all votes entitled to be cast. Holders of Series B Preferred Stock carry 163.0780 votes per share under the filing, which is why the vote totals run to 747,785,652 in aggregate. Those preferred shares are a detail an owner reading only the common-stock count would miss.
Every one of the nine director nominees was elected. Patricia Capel drew the weakest support, with 679,207,529 for and 33,178,909 withheld. The others each had fewer than 6 million withheld votes. Under the filing, directors were elected by plurality, so a heavy withhold count would not have blocked anyone.
The filing also lists a nonbinding advisory vote on named executive officer pay, which passed with 702,266,724 for and 9,960,836 against. The text in the copy we reviewed cuts off before the rest of that count and before the remaining proposal results.
What it means for practices
Analysis: this filing matters less for medspa operators than for the people who hold Coty stock or work inside its professional aesthetics line. Equity grants are a company's internal retention tool. A 50 million share bump gives the board room to pay people in stock rather than cash, and that matters most at a company that has been restructuring. The filing does not say how many shares were already granted or how many remain, so the size of the new reserve against existing commitments is not something we can measure from this document.
The director vote is a small signal. Two million added shares for a board of nine is modest, and the approval rate was high.
What owners can do
If you buy professional skin or body products from Coty's brands, this filing changes nothing you pay or receive. If you are a shareholder or a supplier with a stake in Coty's stock, the full ELTIP and director plan texts are filed as Exhibits 10.1 and 10.2 to the same 8-K, and the summaries are in the September 24, 2026 proxy statement under the headings the filing names. Read the plan terms there, not in our summary. Our summary cannot tell you vesting schedules, performance conditions or eligibility, because the filing points to those exhibits rather than repeating them.
What we don't know yet
The filing does not state the company's current share count, the number of shares already reserved or granted under the old ELTIP, or the cost of the new grants. It does not explain why the board sought the increase at this time. The 8-K is a record of votes, not a statement of strategy. Anything about how Coty plans to use the new shares will have to come from the company's next quarterly report or from the proxy exhibits.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.